Zobrazeno 1 - 10
of 53
pro vyhledávání: '"Daisuke Kato"'
Autor:
Yoshiya Tanaka, Yuichiro Kaneko, Mitsuhiro Rokuda, Hiroyuki Izutsu, Musashi Fukuda, Neil M. Schultz, Daisuke Kato, Tsutomu Takeuchi
Publikováno v:
Arthritis Research & Therapy, Vol 23, Iss 1, Pp 1-14 (2021)
Arthritis Research & Therapy
Arthritis Research & Therapy
Background Peficitinib (ASP015K), a novel oral Janus kinase inhibitor, has demonstrated efficacy and safety in the treatment of patients with rheumatoid arthritis (RA). This study evaluated the effect of peficitinib on patient- and physician-reported
Publikováno v:
Lower Urinary Tract Symptoms
Objectives The aim of this post hoc analysis from the Japanese mirabegron surveillance program was to investigate the safety and effectiveness of mirabegron in male patients with overactive bladder (OAB) symptoms with/without concomitant benign prost
Publikováno v:
Lower Urinary Tract Symptoms
Objective This analysis was conducted to investigate the cardiovascular (CV) safety outcomes from the MILAI II study. MILAI II was conducted to evaluate the long‐term safety and efficacy of antimuscarinic add‐on therapy to mirabegron over 52 week
Autor:
Takanari Toyoda, Teppei Fujioka, Masayuki Mizuno, K. Terada, Noriyuki Matsukawa, Daisuke Kato, Yuto Uchida, Yuta Madokoro
Publikováno v:
Acta Neurologica Scandinavica. 137:432-437
Background Cross-sensitivity of rash has been reported between various antiepileptic drugs (AEDs). However, few studies have determined the frequency and management of cross-sensitivity in patients with super-refractory status epilepticus (SRSE). Aim
Publikováno v:
LUTS: Lower Urinary Tract Symptoms. 11:30-38
Objectives A 12-week post-marketing study was conducted to provide real-world data on Japanese patients with overactive bladder (OAB) initiating treatment with mirabegron. This post-hoc analysis focused on safety and effectiveness of mirabegron in pa
Publikováno v:
Science of The Total Environment. 770:144665
Antidepressants are among the most commonly detected pharmaceuticals in the aquatic environment. As they modulate neurotransmission in nervous systems, behavioural abnormalities among aquatic species are of concern. It is possible to measure the conc
Publikováno v:
International Journal of Urology. 24:757-764
Objectives To evaluate persistence and adherence to mirabegron and antimuscarinics in Japan using data from two administrative databases. Methods The present retrospective study evaluated insurance claims for employees and dependents aged ≤75 years
Publikováno v:
LUTS: Lower Urinary Tract Symptoms. 11:14-23
OBJECTIVES To report interim 1-year results from a 3-year surveillance study evaluating safety, efficacy, and persistence of long-term mirabegron for overactive bladder (OAB). METHODS Patients starting treatment with mirabegron for urinary urgency, d
Publikováno v:
LUTS: Lower Urinary Tract Symptoms. 10:122-130
Objectives To provide real-world data on Japanese patients with overactive bladder (OAB) initiating treatment with the β3-adrenoceptor agonist, mirabegron. This study examined prescribing patterns, adverse drug reaction (ADR) incidence, and treatmen
Publikováno v:
International Journal of Urology. 23:1009-1015
Objectives To assess the effect of 25 or 50 mg mirabegron on cardiovascular end-points and adverse drug reactions in real-world Japanese patients with overactive bladder and cardiovascular disease. Methods Participants had overactive bladder, a histo